<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02730728</url>
  </required_header>
  <id_info>
    <org_study_id>823219</org_study_id>
    <nct_id>NCT02730728</nct_id>
  </id_info>
  <brief_title>Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA</brief_title>
  <official_title>A Randomized Study of Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block for Postoperative Analgesia After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare a single shot block, 24 hours, and 48 hour continuous
      catheter nerve block done via the adductor canal method in adult patients who have under gone
      total knee arthroplasty. Visual analogue scores, opioid consumption, time to up and go,
      ambulation, manual muscle tests, and Tinetti scores up to 72 hours post operatively will be
      used for comparison.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If the patient is willing to participate and signs the consent, he/she will be randomized to
      one of the three treatment groups:

        1. Single shot block

        2. 24 hour catheter

        3. 48 hour catheter

      The choice of anesthetic technique will be at the discretion of the anesthesiologist. In our
      institution we usually advocate for spinal anesthesia for total knee arthroplasty. All
      patients will receive their multimodal perioperative pain protocol (MP3) medication as per
      protocol in the patient receiving area (400 mg of gabapentin, 200 mg of Celecoxib, and 1gm of
      acetaminophen).

      Patients will be monitored during block performance with standard ASA monitors. All patients
      will be receiving 2 L of oxygen via a nasal cannula. Sedatives will be titrated to effect.
      Midazolam 1-2 mg, and fentanyl 50-100 mcg will be used for sedation.

      Block time out will be preformed according to standard operating procedure. All blocks will
      be done under ultrasound guidance. Sonosite S nerve machine will be used with a high
      frequency linear (HFL) US probe with 6-13 MHZ frequency. Both single shot and continuous
      adductor canal block will be performed according to the standard operating practices in our
      department 4. Ultrasound survey at the medial part of the thigh will take place, halfway
      between the superior anterior iliac spine and the patella. In a short axis view, the femoral
      artery will be identified underneath the sartorius muscle, with the vein just inferior and
      the saphenous nerve just lateral to the artery. The needle will be introduced in-plane and 2
      to 3 mL of local anesthesia bolus will be used to verify correct placement of the needle in
      the vicinity of the saphenous nerve in the adductor canal.

      For single shot blocks: A bolus of total volume of 20 ml of ropivicaine 0.5% will be injected
      through the needle.

      For the continuous block: The catheter will be introduced and advanced 2-3 cm beyond the tip
      of the needle under ultrasound visualization. The needle was withdrawn over the catheter.
      Injection of a bolus of 5 ml of ropivacaine 0.5% will take place through the catheter while
      observing the spread of local anesthetic under ultrasound. The catheter hub will be affixed
      to the upper lateral thigh with sterile occlusive dressings and an anchoring device.

      Block success will be defined as a change in cutaneous sensation to touch with an alcohol pad
      in the saphenous nerve distribution over the medial leg within 30min after injection.
      Subjects with successful catheter placement per protocol and nerve block onset were retained
      in the study. Subjects with a failed catheter insertion or misplaced catheter indicated by a
      lack of sensory changes had their catheter replaced or were withdrawn from the study.

      At the conclusion of surgery, the catheters will be connected to a pump that will infuse
      local anesthetic. Ropivicaine 0.2% at 8 ml/hour. In the postoperative anesthesia care unit,
      intermittent boluses of hydromorphone will be used as needed. Postoperative analgesia will
      follow the MP3 protocol. Drugs that are used for the multimodal analgesia protocol include
      acetaminophen (1 gm every 8 hours for 72 hours), celecoxib (200 mg every 8 hours for 72
      hours), Gabapentin (300 mg every 8 hours for one week if the patient is opioid na√Øve and for
      two weeks if patients are opioid tolerant), and oxycodone (5-10-15 mg oral as needed every 4
      hours for pain based on patient reported pain score).

      All patients will receive prophylaxis for postoperative nausea and vomiting (PONV) during
      surgery. The protocol for prophylaxis against PONV include administration of 4 mg of
      dexamethasone after induction of anesthesia and 4 mg of ondansetron 20 minutes before
      recovery from anesthesia. Dexamethasone is withheld if the patient has poorly controlled
      diabetes mellitus (DM). Uncontrolled DM will be defined as random blood glucose above 250
      mg/dl.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2015</start_date>
  <completion_date type="Actual">January 1, 2017</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients With Severe Pain at 48 Hours After Surgery</measure>
    <time_frame>48 hours</time_frame>
    <description>The proportion of patients reporting severe pain, defined as pain score (7-10) through the second postoperative day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Scores at 48 Hours After Surgery</measure>
    <time_frame>48 hours</time_frame>
    <description>Average pain scores 48 hours after surgery. The scale used is the numeric rating pain scale. The scale values range from 0-10/ where 0 is no pain and 10 is the worst pain possible imagined on this scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Recovery After Surgery</measure>
    <time_frame>48 hours</time_frame>
    <description>Cumulative ambulation distance in the second postoperative day measured in feet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented Outcomes</measure>
    <time_frame>48 hours</time_frame>
    <description>Quality of recovery (QoR)-9 score on the second day after surgery. This score is a result of a 9 item questionnaire. Answers to each item/question is scored as (0-1-2). The wort score a patient get in the questionnaire is 0 and the best score is 18, depending on the answer of each of the 9 questions and the sum of the scores of these answers</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Total Knee Arthroplasty</condition>
  <condition>Osteoarthritis</condition>
  <condition>Post Operative Pain Control</condition>
  <arm_group>
    <arm_group_label>Single shot adductor canal block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>24 hour continuous adductor canal block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>48 hour continuous adductor canal block</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>20ml bolus of 0.5% ropivicaine</intervention_name>
    <description>Local anesthetic</description>
    <arm_group_label>Single shot adductor canal block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.2% Ropivicaine at 8 milliliter/hour</intervention_name>
    <description>Local anesthetic</description>
    <arm_group_label>24 hour continuous adductor canal block</arm_group_label>
    <arm_group_label>48 hour continuous adductor canal block</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5ml bolus of 0.5% ropivicaine</intervention_name>
    <description>Local anesthetic</description>
    <arm_group_label>24 hour continuous adductor canal block</arm_group_label>
    <arm_group_label>48 hour continuous adductor canal block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for primary total knee arthroplasty

          -  American Society of Anesthesiologists (ASA) physical status I -III

          -  mentally competent and able to give consent for enrollment in the study

        Exclusion Criteria:

          -  Patient younger than 18 years old

          -  Allergy to local anesthetics, systemic opioids (fentanyl, morphine, hydromorphone, and
             any of the drugs included in the multimodal perioperative pain protocol (MP3)

          -  Revision surgery

          -  Impaired kidney functions and patient with coagulopathy

          -  Chronic pain syndromes; Patients will be defined to have chronic pain if they are
             using regular daily doses of systemic narcotics for the past 3 months prior to the
             surgery

          -  BMI of 40 or more

          -  Pregnancy (positive urine pregnancy test result in Preop area on morning of surgery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil M Elkassabany, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>March 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <results_first_submitted>April 18, 2018</results_first_submitted>
  <results_first_submitted_qc>May 17, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 18, 2018</results_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adductor canal block</keyword>
  <keyword>tinetti score</keyword>
  <keyword>time to up and go test</keyword>
  <keyword>Ambulation distance</keyword>
  <keyword>pain score</keyword>
  <keyword>quality of recovery score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Shot Adductor Canal Block</title>
          <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="P2">
          <title>24 Hour Continuous Adductor Canal Block</title>
          <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="P3">
          <title>48 Hour Continuous Adductor Canal Block</title>
          <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Shot Adductor Canal Block</title>
          <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="B2">
          <title>24 Hour Continuous Adductor Canal Block</title>
          <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="B3">
          <title>48 Hour Continuous Adductor Canal Block</title>
          <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="156"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="9.6"/>
                    <measurement group_id="B2" value="66.5" spread="8.5"/>
                    <measurement group_id="B3" value="62.2" spread="8.7"/>
                    <measurement group_id="B4" value="64" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patients With Severe Pain at 48 Hours After Surgery</title>
        <description>The proportion of patients reporting severe pain, defined as pain score (7-10) through the second postoperative day</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Shot Adductor Canal Block</title>
            <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>24 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O3">
            <title>48 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Severe Pain at 48 Hours After Surgery</title>
          <description>The proportion of patients reporting severe pain, defined as pain score (7-10) through the second postoperative day</description>
          <units>percentage of patients with severe pain</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Scores at 48 Hours After Surgery</title>
        <description>Average pain scores 48 hours after surgery. The scale used is the numeric rating pain scale. The scale values range from 0-10/ where 0 is no pain and 10 is the worst pain possible imagined on this scale</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Shot Adductor Canal Block</title>
            <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>24 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O3">
            <title>48 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Scores at 48 Hours After Surgery</title>
          <description>Average pain scores 48 hours after surgery. The scale used is the numeric rating pain scale. The scale values range from 0-10/ where 0 is no pain and 10 is the worst pain possible imagined on this scale</description>
          <units>units on a scale ( Pain score)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" spread="2"/>
                    <measurement group_id="O2" value="4.3" spread="2.5"/>
                    <measurement group_id="O3" value="3.9" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Recovery After Surgery</title>
        <description>Cumulative ambulation distance in the second postoperative day measured in feet</description>
        <time_frame>48 hours</time_frame>
        <population>cumulative ambulation distance in second day after surgery</population>
        <group_list>
          <group group_id="O1">
            <title>Single Shot Adductor Canal Block</title>
            <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>24 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O3">
            <title>48 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Recovery After Surgery</title>
          <description>Cumulative ambulation distance in the second postoperative day measured in feet</description>
          <population>cumulative ambulation distance in second day after surgery</population>
          <units>Feet</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155" lower_limit="62" upper_limit="240"/>
                    <measurement group_id="O2" value="150" lower_limit="70" upper_limit="240"/>
                    <measurement group_id="O3" value="200" lower_limit="90" upper_limit="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient-oriented Outcomes</title>
        <description>Quality of recovery (QoR)-9 score on the second day after surgery. This score is a result of a 9 item questionnaire. Answers to each item/question is scored as (0-1-2). The wort score a patient get in the questionnaire is 0 and the best score is 18, depending on the answer of each of the 9 questions and the sum of the scores of these answers</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Shot Adductor Canal Block</title>
            <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O2">
            <title>24 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
          <group group_id="O3">
            <title>48 Hour Continuous Adductor Canal Block</title>
            <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
          </group>
        </group_list>
        <measure>
          <title>Patient-oriented Outcomes</title>
          <description>Quality of recovery (QoR)-9 score on the second day after surgery. This score is a result of a 9 item questionnaire. Answers to each item/question is scored as (0-1-2). The wort score a patient get in the questionnaire is 0 and the best score is 18, depending on the answer of each of the 9 questions and the sum of the scores of these answers</description>
          <units>units on a scale ( QoR score)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="11" upper_limit="14"/>
                    <measurement group_id="O2" value="13" lower_limit="11" upper_limit="15"/>
                    <measurement group_id="O3" value="13" lower_limit="12" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Shot Adductor Canal Block</title>
          <description>adductor canal block group will receive single shot adductor canal block with 20ml bolus of 0.5% ropivicaine for analgesia after TKA
20ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="E2">
          <title>24 Hour Continuous Adductor Canal Block</title>
          <description>adductor canal block group will receive 24 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
        <group group_id="E3">
          <title>48 Hour Continuous Adductor Canal Block</title>
          <description>adductor canal block group will receive 48 hour continuous adductor canal block (0.2% Ropivicaine at 8 milliliter/hour) with initial 5ml bolus of 0.5% Ropivicaine for analgesia after TKA
0.2% Ropivicaine at 8 milliliter/hour: Local anesthetic
5ml bolus of 0.5% ropivicaine: Local anesthetic</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Nabil Elkassabany</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>2156628000</phone>
      <email>nabil.elkassabany@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

